2025 Q4 -tulosraportti
UUTTA
7 päivää sitten
‧48 min
Tarjoustasot
Oslo Børs
Määrä
Osto
1 155
Myynti
Määrä
269
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 250 | - | - | ||
| 1 880 | - | - | ||
| 985 | - | - | ||
| 135 | - | - | ||
| 100 | - | - |
Ylin
59,9VWAP
Alin
57,6VaihtoMäärä
1,9 33 021
VWAP
Ylin
59,9Alin
57,6VaihtoMäärä
1,9 33 021
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 19.2.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·4 t sittenThis is honestly starting to look like a small tragicomedy. For several years, we have been served promises, presentations, and optimistic formulations about the approval of Cevira APL-1702, fronted and analyzed extensively. Yet here we sit., waiting and waiting a bit more! Cevira APL-1702 has allegedly been in the final phase for over six months now. «Final phase» sounds dramatic and action-packed, but in practice, it feels more like an eternal waiting signal. Yes, regulatory processes take time. Yes, authorities take the time they need. But when the market has been promised progress for a long time, «stagnation» becomes difficult to sell as strategic patience. Perhaps the most ironic thing is how binary the situation has become. The stock lives and dies with a single approval. The company performs quite well operationally given the circumstances, but it seems as if parts of the market have completely disengaged from fundamental analysis and instead only stare at a single date that never quite materializes. Objectively speaking, long processing times in regulatory processes are not uncommon. But communication creates expectations, and expectations that are not met in time create frustration. When «soon» has lasted for half a year, even the most patient investors begin to wonder if the calendar and reality operate on different time scales.
·1 t sitten · MuokattuSo: what are you talking about? PHO itself has "guided" H1 2026 for Cevira clarification. They cannot, in any case, comment precisely or go into detail, as only Asieris in China can comment on the process. We KNOW that Cevira is in the very last technical round for approval. THAT was confirmed/occurred only in December (if I remember correctly), when it exited the public processing list/queue of the CDE. And PHO's guiding therefore seems to be spot-on. The company is also not binary. Hex will be released soon in China. There might be a reclassification in the USA. And so on. But thanks for playing. That Cevira *could* have been approved as early as spring 2025 is another discussion. That didn't happen as there was an extra review round and additional information was requested. It's a device-drug combo, so not particularly surprising in retrospect.
·1 päivä sittenhope it turns upwards soon1 päivä sitten1 päivä sitten🤷
·17 t sittenThose who buy for that revenue growth are, to put it mildly, no genius. But revenue growth will skyrocket with: downgrading, flex, wolfscope kina, cevira kina+worldwide.- ·18.2.Exciting presentation, no doubt that the core business is growing and opex is under control. Then comes cevira and hexvix China as a cherry on top.
20.2.20.2.Not sure what you mean - but mgt is far from explosive growth - so 2026 will be another loss making year, i think - ·18.2.The algo package has finished shaking out retails. Bon voyage.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2025 Q4 -tulosraportti
UUTTA
7 päivää sitten
‧48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·4 t sittenThis is honestly starting to look like a small tragicomedy. For several years, we have been served promises, presentations, and optimistic formulations about the approval of Cevira APL-1702, fronted and analyzed extensively. Yet here we sit., waiting and waiting a bit more! Cevira APL-1702 has allegedly been in the final phase for over six months now. «Final phase» sounds dramatic and action-packed, but in practice, it feels more like an eternal waiting signal. Yes, regulatory processes take time. Yes, authorities take the time they need. But when the market has been promised progress for a long time, «stagnation» becomes difficult to sell as strategic patience. Perhaps the most ironic thing is how binary the situation has become. The stock lives and dies with a single approval. The company performs quite well operationally given the circumstances, but it seems as if parts of the market have completely disengaged from fundamental analysis and instead only stare at a single date that never quite materializes. Objectively speaking, long processing times in regulatory processes are not uncommon. But communication creates expectations, and expectations that are not met in time create frustration. When «soon» has lasted for half a year, even the most patient investors begin to wonder if the calendar and reality operate on different time scales.·1 t sitten · MuokattuSo: what are you talking about? PHO itself has "guided" H1 2026 for Cevira clarification. They cannot, in any case, comment precisely or go into detail, as only Asieris in China can comment on the process. We KNOW that Cevira is in the very last technical round for approval. THAT was confirmed/occurred only in December (if I remember correctly), when it exited the public processing list/queue of the CDE. And PHO's guiding therefore seems to be spot-on. The company is also not binary. Hex will be released soon in China. There might be a reclassification in the USA. And so on. But thanks for playing. That Cevira *could* have been approved as early as spring 2025 is another discussion. That didn't happen as there was an extra review round and additional information was requested. It's a device-drug combo, so not particularly surprising in retrospect.
- ·1 päivä sittenhope it turns upwards soon1 päivä sitten1 päivä sitten🤷·17 t sittenThose who buy for that revenue growth are, to put it mildly, no genius. But revenue growth will skyrocket with: downgrading, flex, wolfscope kina, cevira kina+worldwide.
- ·18.2.Exciting presentation, no doubt that the core business is growing and opex is under control. Then comes cevira and hexvix China as a cherry on top.20.2.20.2.Not sure what you mean - but mgt is far from explosive growth - so 2026 will be another loss making year, i think
- ·18.2.The algo package has finished shaking out retails. Bon voyage.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
1 155
Myynti
Määrä
269
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 250 | - | - | ||
| 1 880 | - | - | ||
| 985 | - | - | ||
| 135 | - | - | ||
| 100 | - | - |
Ylin
59,9VWAP
Alin
57,6VaihtoMäärä
1,9 33 021
VWAP
Ylin
59,9Alin
57,6VaihtoMäärä
1,9 33 021
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 19.2.2025 |
2025 Q4 -tulosraportti
UUTTA
7 päivää sitten
‧48 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q1 -tulosraportti 7.5. |
| Menneet tapahtumat | ||
|---|---|---|
2025 Q4 -tulosraportti 18.2. | ||
2025 Q3 -tulosraportti 29.10.2025 | ||
2025 Q2 -tulosraportti 30.7.2025 | ||
2025 Q1 -tulosraportti 8.5.2025 | ||
2024 Q4 -tulosraportti 19.2.2025 |
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·4 t sittenThis is honestly starting to look like a small tragicomedy. For several years, we have been served promises, presentations, and optimistic formulations about the approval of Cevira APL-1702, fronted and analyzed extensively. Yet here we sit., waiting and waiting a bit more! Cevira APL-1702 has allegedly been in the final phase for over six months now. «Final phase» sounds dramatic and action-packed, but in practice, it feels more like an eternal waiting signal. Yes, regulatory processes take time. Yes, authorities take the time they need. But when the market has been promised progress for a long time, «stagnation» becomes difficult to sell as strategic patience. Perhaps the most ironic thing is how binary the situation has become. The stock lives and dies with a single approval. The company performs quite well operationally given the circumstances, but it seems as if parts of the market have completely disengaged from fundamental analysis and instead only stare at a single date that never quite materializes. Objectively speaking, long processing times in regulatory processes are not uncommon. But communication creates expectations, and expectations that are not met in time create frustration. When «soon» has lasted for half a year, even the most patient investors begin to wonder if the calendar and reality operate on different time scales.·1 t sitten · MuokattuSo: what are you talking about? PHO itself has "guided" H1 2026 for Cevira clarification. They cannot, in any case, comment precisely or go into detail, as only Asieris in China can comment on the process. We KNOW that Cevira is in the very last technical round for approval. THAT was confirmed/occurred only in December (if I remember correctly), when it exited the public processing list/queue of the CDE. And PHO's guiding therefore seems to be spot-on. The company is also not binary. Hex will be released soon in China. There might be a reclassification in the USA. And so on. But thanks for playing. That Cevira *could* have been approved as early as spring 2025 is another discussion. That didn't happen as there was an extra review round and additional information was requested. It's a device-drug combo, so not particularly surprising in retrospect.
- ·1 päivä sittenhope it turns upwards soon1 päivä sitten1 päivä sitten🤷·17 t sittenThose who buy for that revenue growth are, to put it mildly, no genius. But revenue growth will skyrocket with: downgrading, flex, wolfscope kina, cevira kina+worldwide.
- ·18.2.Exciting presentation, no doubt that the core business is growing and opex is under control. Then comes cevira and hexvix China as a cherry on top.20.2.20.2.Not sure what you mean - but mgt is far from explosive growth - so 2026 will be another loss making year, i think
- ·18.2.The algo package has finished shaking out retails. Bon voyage.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Oslo Børs
Määrä
Osto
1 155
Myynti
Määrä
269
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| 250 | - | - | ||
| 1 880 | - | - | ||
| 985 | - | - | ||
| 135 | - | - | ||
| 100 | - | - |
Ylin
59,9VWAP
Alin
57,6VaihtoMäärä
1,9 33 021
VWAP
Ylin
59,9Alin
57,6VaihtoMäärä
1,9 33 021
Välittäjätilasto
Dataa ei löytynyt